Drug Profile

3HP 2827

Alternative Names: 3HP-2827

Latest Information Update: 03 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 3H Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action Type-2 fibroblast growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

02 Jun 2026 Efficacy, adverse event and pharmacokinetic data from a phase I trial in Solid tumours presented at the 62^ndAnnual Meeting of the American Society of Clinical Oncology (ASCO-2026)
02 Jun 2026 Safety and efficacy data from a phase-I clinical trials in Solid tumours released by 3H Pharmaceuticals
17 Jun 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease) in China (PO) (NCT06378593)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com